EUVIMEDEUVIMED entdecken
Vergleichsstudie

Economic value of toripalimab plus axitinib as first-line treatment for advanced renal cell carcinoma in China: a model-based cost-effectiveness analysis

Shuo Kang iD, Jintuo Yin

Expert Review of Pharmacoeconomics & Outcomes Research · 2024

DOI: 10.1080/14737167.2024.2333334 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Expert Review of Pharmacoeconomics & Outcomes Research, 2024. Verfasst von Shuo Kang und 1 weiteren Autor:innen. Beteiligte Einrichtung: Medical Insurance Office, The Second Hospital of Hebei Medical University, Shijiazhuang, PR China. Hauptthemen laut MEDLINE: Axitinib, Carcinoma, Renal Cell, Cost-Benefit Analysis, Quality-Adjusted Life Years. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 32 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE: The current analysis aimed to evaluate the economic benefit of toripalimab plus axitinib for previously untreated RCC patients from the Chinese healthcare system perspective. METHODS: The partitioned survival model was developed to simulate 3-week patients' transition in 20-year time horizon to evaluate the cost-effectiveness of toripalimab plus axitinib compared with sunitinib for advanced RCC. Survival data were gathered from the RENOTORCH trial, and cost and utility inputs were obtained from the database and published literature. Total cost, life-years (LYs), quality-adjusted life-years (QALYs), and incremental cost-effectiveness ratio (ICER) were the model outputs. Subgroup analyses and sensitivity analyses were conducted to increase the comprehensiveness and estimate the robustness of the model results. RESULTS: In the base-case analysis, compared with sunitinib, toripalimab plus axitinib could bring additional 1.19 LYs and 0.65 QALYs, with the marginal cost of $41,499.23, resulting in the ICER of $64,337.49/QALY, which is higher than the WTP threshold. And ICERs were always beyond the WTP threshold of all subgroups. Sensitivity analyses demonstrated the model results were robust. CONCLUSIONS: Toripalimab plus axitinib was unlikely to be the cost-effective first-line therapy for patients with previously untreated advanced RCC compared with sunitinib from the Chinese healthcare system perspective.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AxitinibCarcinoma, Renal CellCost-Benefit AnalysisQuality-Adjusted Life YearsKidney NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsAntibodies, Monoclonal, HumanizedModels, EconomicSunitinibHumansChinaCost-Effectiveness Analysis

Stichwörter der Autor:innen

Toripalimabadvanced renal cell carcinomaaxitinibcost-effectiveness analysispartitioned survival modelsunitinib

Substanzen

AxitinibAntibodies, Monoclonal, HumanizedSunitinibtoripalimab

Autor:innen und Institutionen

  • Medical Insurance Office, The Second Hospital of Hebei Medical University, Shijiazhuang, PR China.
  • Department of Pharmacy, The Fourth Hospital of Hebei Medical University, Shijiazhuang, PR China.

ORCID-Profile: Shuo Kang

Zitieren

APA

Kang, S., & Yin, J. (2024). Economic value of toripalimab plus axitinib as first-line treatment for advanced renal cell carcinoma in China: a model-based cost-effectiveness analysis. Expert Review of Pharmacoeconomics & Outcomes Research. https://doi.org/10.1080/14737167.2024.2333334

Vancouver

Kang S, Yin J. Economic value of toripalimab plus axitinib as first-line treatment for advanced renal cell carcinoma in China: a model-based cost-effectiveness analysis. Expert Review of Pharmacoeconomics & Outcomes Research. 2024. doi:10.1080/14737167.2024.2333334

BibTeX
@article{Kang2024,
  author = {Kang, Shuo and Yin, Jintuo},
  title = {Economic value of toripalimab plus axitinib as first-line treatment for advanced renal cell carcinoma in China: a model-based cost-effectiveness analysis},
  journal = {Expert Review of Pharmacoeconomics & Outcomes Research},
  year = {2024},
  doi = {10.1080/14737167.2024.2333334}
}
Kostenlos starten →